000 02317cam  2200385zi 4500
0019.893026
003CaOODSP
00520221107173331
006m     o  d f      
007cr cn|||||||||
008201029t20202020onc     o    f000 0 eng d
020 |a9780660364803
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-302/2020E-PDF
24500|aGuidance document : |bcomparative pharmacokinetic studies for orally inhaled products.
24610|aComparative pharmacokinetic studies for orally inhaled products
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2020.
264 4|c©2020
300 |a1 online resource (11 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |aIssued also in HTML format.
500 |a"Effective date: 2020/12/21."
500 |aIssued also in French under title: Ligne directrice : études pharmacocinétiques comparatives sur les produits administrés par inhalation orale.
520 |a"Comparative pharmacokinetic studies should be conducted in accordance with generally accepted clinical practices. These practices are designed to ensure the protection of the rights, safety and well-being of subjects. Good Clinical Practices are referred to in Division 5 of the Regulations, and described in the International Council for Harmonisation (ICH) Guidance (Topic E6) on Good Clinical Practice. To ensure compliance with the Regulations, follow the recommendations included in this guidance respecting study design and the conduct of comparative pharmacokinetic studies involving subsequent-entry orally inhaled drug products (OIPs)"--Policy statement, page 5.
650 0|aPharmacokinetics.
650 0|aOral medication|xGovernment policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLigne directrice : |w(CaOODSP)9.893028
85640|qPDF|s250 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-302-2020-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/comparative-pharmacokinetic-studies-orally-inhaled-products-2020.html